Pfizer says U.S. court invalidates Celebrex patent; generics loom

(Reuters) - A U.S. court ruled invalid a patent covering Pfizer Inc's blockbuster Celebrex painkiller, the drugmaker said, giving generic rivals an earlier U.S. entry that analysts estimated could cost the company $3 billion in revenue by the end of 2015.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news